Cisplatin every three weeks versus weekly cisplatin or carboplatin with definitive radiotherapy for squamous cell carcinoma of the head and neck is associated with improved overall survival in a representative national population.

Authors

Michael Gerard McCusker

University of Maryland Medical Center, Baltimore, MD

Michael Gerard McCusker , Ranee Mehra , Jason K. Molitoris , Rodney Taylor , Kevin J. Cullen , Olga G. Goloubeva

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.

First Author: Thiago Bueno Oliveira Sr.

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Randomised phase II study with cetuximab in combination with 5-FU and cisplatin or carboplatin versus cetuximab in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck (CETMET trial).

First Author: Signe Friesland

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

First Author: Makoto Tahara

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Six-year follow-up from the weekly-three-weekly study comparing cisplatin once-a-week to once-every-three-weeks as concurrent chemoradiation for locally advanced head and neck squamous cell carcinoma.

First Author: Vanita Noronha